Aquinox Pharmaceuticals To Present At 2015 Bloom Burton & Co. Healthcare Investor Conference
VANCOUVER, British Columbia, April 27, 2015 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox's President & CEO, will present a corporate overview at the upcoming 2015 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 5that 11:00 AM Eastern Time. The conference will take place at the Sheraton Centre in Toronto, ON.
The corporate overview being presented will be available at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Having successfully completed multiple preclinical studies and clinical trials with AQX-1225, Aquinox is now advancing through Phase 2 development. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Senior Manager, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.629.9223 Ext. 109
ir@aqxpharma.com
Communications C ontact Info:
Bianca Nery
Senior Account Executive
MacDougall Biomedical Communications
650.339.7533
aquinox@macbiocom.com
Help employers find you! Check out all the jobs and post your resume.